Vitalize, CIDP Clinical Trial

VITALIZE (EFC18156)

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (VITALIZE)

The purpose of the study is to evaluate effects and safety of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg.

This study uses an investigational medication called riliprubart. The investigational medicine is injected in a vein or under the skin via an autoinjector, either at the clinic or at home (self -administered). It blocks a particular part of the body’s defense system from being overactive.

In this study you will have a 50% chance of receiving either intravenous immunoglobulin (IVIg) or the investigational medication (riliprubart) initially for 24 weeks (5 ½ months) and then will receive the investigational medication (riliprubart) for the remaining 24 weeks (5 ½ months).

For more information on this Phase 3 study and to complete a pre-screening questionnaire please visit: www.sanofistudies.com/NBRX.

For a list of clinical trial sites https://clinicaltrials.gov/study/NCT06290141.

United Kingdom	https://www.sanofistudies.com/NPUK/
CIDP Foundation Sweden	https://www.sanofistudies.com/KM1D/
CIDP Foundation Spain	https://www.sanofistudies.com/GZ20/
CIDP Foundation Mexico	https://www.sanofistudies.com/LV6J/
CIDP Foundation Germany	https://www.sanofistudies.com/WQAV/
CIDP Foundation Czechia	https://www.sanofistudies.com/APJN/
CIDP Foundation CA/FR	https://www.sanofistudies.com/9O2H/
CIDP Foundation CA/EN	https://www.sanofistudies.com/RJXE/
CIDP Foundation US/EN	https://www.sanofistudies.com/NBRX/